Peking University Pharmaceuticals announced that New Advantage International, the controlling shareholder of Synthesis Group, the controlling shareholder of the company, previously agreed to transfer 100% of Synthesis Group's shares and related claims to Shanghai Hongkang; on October 26, 2026, the transfer of shares in Synthesis Group completed the registration of industrial and commercial changes. After the transaction was completed, Synthesis Group was still the controlling shareholder of the company. Shanghai Hongkang indirectly held 109 million shares of the company, accounting for 18.29% of the total share capital; Xu Xiren was no longer the actual controller, and Cheng Dong became the actual controller.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.